TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00567190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab was administered as an intravenous (IV) loading dose of 840 milligrams (mg) q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420 mg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (matching pertuzumab) was administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab was administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab was administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel was administered as an IV dose of 75 milligrams per square meter of body surface area (mg/m\^2) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. On or prior to Cycle 6, docetaxel was only to be discontinued for progressive disease or unmanageable toxicity. After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel was administered as an IV dose of 75 milligrams per square meter of body surface area (mg/m\^2) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. On or prior to Cycle 6, docetaxel was only to be discontinued for progressive disease or unmanageable toxicity. After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician.
Study: NCT00406133

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitor
Description: Daily use of a continuous glucose monitor
Study: NCT04549610

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB supplementation
Description: Group taking oral HMB supplementation in a blinded capsule form.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Group taking oral supplementation with placebo (corn starch) in a blinded capsule form.
Study: NCT00227617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: 200mg/m2 IV q2 wk on day 1 over a 2-hour period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 200mg/m2 IV q 2 wk on day 1 over a 2-hour period
Study: NCT04424420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen oral tablet
Study: NCT01826812

Intervention type: OTHER
Intervention: 30 minutes sustained reading
Description: The participants will be given a text to read silently in 30 minutes.

Intervention type: OTHER
Intervention: 30 minutes sustained reading
Description: The participants will be given a text to read silently in 30 minutes.

Intervention type: OTHER
Intervention: Dry eye exam
Description: Tear break-up time, tear collection, osmolarity, Schirmer test, corneal and conjunctival staining.

Intervention type: OTHER
Intervention: Dry eye exam
Description: Tear break-up time, tear collection, osmolarity, Schirmer test, corneal and conjunctival staining.
Study: NCT04602533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy) Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities.

Intervention type: DRUG
Group type: OTHER
Intervention: standard of care
Description: Radiochemotherapy: Cisplatin (75 mg/m² (BSA) D1#) or alternatively Carboplatin (AUC 5 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours or more between fractions) with start at latest at beginning of cycle 3, ideally during cycle 1) followed by prophylactic cranial irradiation (PCI, if clinically indicated and according to local standard at any time after completion of radio-chemotherapy))~A simultaneous administration of platinum-based chemotherapy (preferred Cisplatin) and radiotherapy for at least 2 cycles should be performed.
Study: NCT01326858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride ophthalmic solution, 0.7%
Description: Treatment A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine hydrochloride ophthalmic solution, 0.7%
Description: Treatment A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine hydrochloride ophthalmic solution, 0.7%
Description: Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride ophthalmic solution vehicle
Description: Treatment B, inactive ingredients used as placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine hydrochloride ophthalmic solution vehicle
Description: Treatment B, inactive ingredients used as placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine hydrochloride ophthalmic solution vehicle
Description: Treatment B, inactive ingredients used as placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate ophthalmic solution, 0.025%
Description: Treatment C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketotifen fumarate ophthalmic solution, 0.025%
Description: Treatment C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen fumarate ophthalmic solution, 0.025%
Description: Treatment C
Study: NCT02671032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus CI532 cochlear implant
Study: NCT04424420

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Sugar pill manufactured to mimic the Paracetamol and Ibuprofen.
Study: NCT02359487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-HIV Risk Reduction Counseling
Description: The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
Study: NCT00135005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMN107, STI571
Study: NCT01921296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine
Description: 5 milligrams orally 2 hours before bedtime
Study: NCT02083016

Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation guided by conventional mapping.
Description: Substrate mapping and ablation of ventricular tachycardia.

Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation guided by ultra-high density mapping with multielectrode catheter.
Description: Substrate mapping and ablation of ventricular tachycardia.
Study: NCT04029129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air filtration and building envelop modifications
Description: Air filters and closing and sealing of windows and doors was used to reduce infiltration of air pollution from outdoors in rooms next to major highways at rush hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air filtration and building envelop modifications
Description: Air filters and closing and sealing of windows and doors was used to reduce infiltration of air pollution from outdoors in rooms next to major highways at rush hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air filtration and building envelop modifications
Description: Air filters and closing and sealing of windows and doors was used to reduce infiltration of air pollution from outdoors in rooms next to major highways at rush hour.
Study: NCT00846872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GHRP-3 low dose
Description: 0.1 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GHRP-3 high dose
Description: 0.5 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 5% mannitol will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
Study: NCT03663686

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Litapiprant Tablet
Description: Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Litapiprant Tablet
Description: Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Litapiprant Tablet
Description: Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells
Study: NCT02359487

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intervention
Description: Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
Study: NCT04058093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Training Program
Description: Functional training program (FTP) include:~1. Functional training sessions will be oriented by graduates or masters in sport with the supervision of a sports medicine doctor;~2. Group nutrition counseling, in the form of healthy cooking classes direct by nutritionists with the support of culinary students.
Study: NCT01377922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine Phosphate
Description: Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.
Study: NCT03663686

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Litapiprant Tablet
Description: Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Litapiprant Tablet
Description: Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Litapiprant Tablet
Description: Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Litapiprant Tablet
Description: Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells
Study: NCT01151800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using IVR to maintain ACS patients on best practice guidelines
Study: NCT01270269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Physical and functional rehabilitation
Description: A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Cognitive, physical, & functional rehabilitation
Description: A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
Study: NCT01377922

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
Study: NCT01685138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: LDK378/Ceritinib was supplied as 150 mg hard gelatin capsules and administered orally
Study: NCT01313286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2608204 Reference
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2608204 Reference
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2608204 Test
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2608204 Test
Description: Administered orally.
Study: NCT03210155

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Stim AID CES (Active Comparator)
Description: The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Alpha-Stim AID CES (Sham Comparator)
Description: The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
Study: NCT02361515

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Moderate hypofractionated radiotherapy
Description: Moderate hypofractionated radiotherapy of 62Gy in 20 fraction of 3.1Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Stereotactic radiotherapy of 37.5Gy in 5 fraction of 7.5Gy.
Study: NCT00438880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agatolimod Sodium
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Indium In-111 Ibritumomab Tiuxetan
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo imaging scans

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo imaging scans

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y-90 Ibritumomab Tiuxetan
Description: Given IV
Study: NCT04050774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance boards
Description: The unstable surface will be created with a balance board consisting of a wooden board mounted on a section of a cylinder, creating an unstable support in the sagittal plane or in the frontal plane. The participants will stand on three balance boards, varying the height of the surface of the board above the point of contact (15, 17 and 19 cm respectively). The radius of the cylinder will kept constant at 24 cm. The standing surface will be 48cm x 48 cm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance boards
Description: The unstable surface will be created with a balance board consisting of a wooden board mounted on a section of a cylinder, creating an unstable support in the sagittal plane or in the frontal plane. The participants will stand on three balance boards, varying the height of the surface of the board above the point of contact (15, 17 and 19 cm respectively). The radius of the cylinder will kept constant at 24 cm. The standing surface will be 48cm x 48 cm
Study: NCT01146899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider Alert
Description: Provider influenza vaccine alert
Study: NCT04594070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Iron supplementation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Iron supplementation
Study: NCT02601989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Per oral intake of placebo for six weeks
Study: NCT03222089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 165 mg/m² 1-hour IV day 1
Study: NCT04569630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled hypoglycaemic state while driving
Description: Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Driving data will be recorded in 4 subsequent glycemic states using an adapted hypoglycemic clamp protocol: euglycemia (d1, 5-8 mmol/l), progressive hypoglycaemia (d2, declining from 4.5 to 2.5 mmol/l), stable hypoglycemia (d3, 2.0-2.5 mmol/l), and again in euglycaemia (d4, 5-8 mmol/l). Patients will be blinded to their glucose levels.
Study: NCT01258634

Intervention type: DRUG
Group type: OTHER
Intervention: Dexrazoxane
Description: Preoperative Chemotherapy Courses 1, 2, 3, 4: 750mg/m2; IV over 15 minutes on day 1~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 750mg/m2 IV over 15 minutes on Day 1~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 750mg/m2 IV over 15 minutes on Day 1

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Preoperative Chemotherapy Courses 1 and 3: 75mg/m2; IV push day 1 Courses 2 and 4: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Good Responders Course 1: 75mg/m2; IV push day 1 Course 2: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Poor Responders Course 2: 75mg/m2; IV push day 1 Course 4: 75mg/m2; IV push day 1, hour 0

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Preoperative Chemotherapy Courses 1 and 3: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Poor Responders:~Course 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol

Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF
Description: Preoperative Chemotherapy Courses 1, 2, 3, and 4: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000~Postoperative Chemotherapy for Poor Responders Courses 2, 4, and 5: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000

Intervention type: DRUG
Group type: OTHER
Intervention: PEG-filgrastim
Description: Preoperative Chemotherapy Courses 1, 2, 3, and 4: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 6mg; SQ starting 24 hours after chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Etoposide
Description: Preoperative Chemotherapy Courses 2 and 4: 50mg/m2 on days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 50mg/m2 on days 1, 2, 3, 4 Course 3: 50mg/m2 on days, 1, 2, 3, 4 Hour 0-1~Postoperative Chemotherapy for Poor Responders Course 4: 50mg/m2 on days 1, 2, 3, 4 Course 5: 50mg/m2 on days 1, 2, 3, 4

Intervention type: DRUG
Group type: OTHER
Intervention: Ifosfamide
Description: Preoperative Chemotherapy Courses 2 and 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 3: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Poor Responders Course 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 5: 3g/m2; IV over 1 hour Days 1, 2, 3, 4
Study: NCT03222089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 165 mg/m² 1-hour IV day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin 85 mg/m² 2-hours IV day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: oxaliplatin 85 mg/m² 2-hours IV day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoleucovorin
Description: Levoleucovorin 200 mg/m² 2-hours IV day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levoleucovorin
Description: Levoleucovorin 200 mg/m² 2-hours IV day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 2800 mg/m² 46-hours flat continuous infusion IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU 2800 mg/m² 46-hours flat continuous infusion IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF 150ug s.c. d3-7 , Repeated every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.